Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhamed Baljevic

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Transplantation and Cellular Therapy|August 23, 2024
No Role for Tandem Autologous Stem Cell Transplantation in Modern Treatment Paradigms for Transplant Eligible Multiple MyelomaMuhamed Baljevic, Eden Ayele Biltibo, Bhagirathbhai Dholaria, et al.
Case Reports in Hematology|March 11, 2015
Epstein-barr virus-related hemophagocytic lymphohistiocytosis: hematologic emergency in the critical care settingNeda Hashemi-Sadraei, Pimprapa Vejpongsa, Muhamed Baljevic, et al.
Frontiers in Immunology|November 13, 2023
Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitorsAdam F Binder, Christopher J Walker, Tomer M Mark, et al.
Maedica|June 6, 2018
Serendipitous Discovery of Factor VII Deficiency and the Ensuing DilemmaJayadev M Umakanthan, Prajwal Dhakal, Krishna Gundabolu, et al.
Journal of Thrombosis and Haemostasis : JTH|January 7, 2026
"Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT": comment from Galarza Fortuna et alGliceida M Galarza Fortuna, Kian J Rahbari, Muhamed Baljevic, et al.
Frontiers in Oncology|October 8, 2025
Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacyMuhamed Baljevic, Gary Schiller, Tomer M Mark, et al.
Cancers|February 13, 2026
Ex Vivo Treatment Response Prediction in Multiple Myeloma: Assay Formats, Clinical Correlation, and Future DirectionsGavin R Oliver, Carlton C Barnett, Kendra E Hightower, et al.
American Journal of Hematology|March 12, 2021
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significanceJorge J Castillo, Natalie S Callander, Muhamed Baljevic, et al.
Cureus|January 13, 2022
Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical TherapySwethika H Sundaravel, Rosalyn I Marar, Muhannad A Abbasi, et al.
British Journal of Haematology|May 10, 2026
Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myelomaKian J Rahbari, Gliceida M Galarza Fortuna, Bhagirathbhai Dholaria, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Transplantation and Cellular Therapy|August 23, 2024
No Role for Tandem Autologous Stem Cell Transplantation in Modern Treatment Paradigms for Transplant Eligible Multiple MyelomaMuhamed Baljevic, Eden Ayele Biltibo, Bhagirathbhai Dholaria, et al.
Case Reports in Hematology|March 11, 2015
Epstein-barr virus-related hemophagocytic lymphohistiocytosis: hematologic emergency in the critical care settingNeda Hashemi-Sadraei, Pimprapa Vejpongsa, Muhamed Baljevic, et al.
Frontiers in Immunology|November 13, 2023
Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitorsAdam F Binder, Christopher J Walker, Tomer M Mark, et al.
Maedica|June 6, 2018
Serendipitous Discovery of Factor VII Deficiency and the Ensuing DilemmaJayadev M Umakanthan, Prajwal Dhakal, Krishna Gundabolu, et al.
Journal of Thrombosis and Haemostasis : JTH|January 7, 2026
"Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT": comment from Galarza Fortuna et alGliceida M Galarza Fortuna, Kian J Rahbari, Muhamed Baljevic, et al.
Frontiers in Oncology|October 8, 2025
Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacyMuhamed Baljevic, Gary Schiller, Tomer M Mark, et al.
Cancers|February 13, 2026
Ex Vivo Treatment Response Prediction in Multiple Myeloma: Assay Formats, Clinical Correlation, and Future DirectionsGavin R Oliver, Carlton C Barnett, Kendra E Hightower, et al.
American Journal of Hematology|March 12, 2021
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significanceJorge J Castillo, Natalie S Callander, Muhamed Baljevic, et al.
Cureus|January 13, 2022
Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical TherapySwethika H Sundaravel, Rosalyn I Marar, Muhannad A Abbasi, et al.
British Journal of Haematology|May 10, 2026
Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myelomaKian J Rahbari, Gliceida M Galarza Fortuna, Bhagirathbhai Dholaria, et al.
Pageof 6